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Abstract
Background: Sharing the common neuroectodermal origin, melanoma and neuroblastoma are tumors widely 
diffused among adult and children, respectively. Clinical prognosis of aggressive neuroectodermal cancers remains 
dismal, therefore the search for novel therapies against such tumors is warranted. Curcumin is a phytochemical 
compound widely studied for its antioxidant, anti-inflammatory and anti-cancer properties. Recently, we have 
synthesized and tested in vitro various curcumin-related compounds in order to select new anti-tumor agents 
displaying stronger and selective growth inhibition activity on neuroectodermal tumors.
Results: In this work, we have demonstrated that the new α,β-unsaturated ketone D6 was more effective in inhibiting 
tumor cells growth when compared to curcumin. Normal fibroblasts proliferation was not affected by this treatment. 
Clonogenic assay showed a significant dose-dependent reduction in both melanoma and neuroblastoma colony 
formation only after D6 treatment. TUNEL assay, Annexin-V staining, caspases activation and PARP cleavage unveiled 
the ability of D6 to cause tumor cell death by triggering apoptosis, similarly to curcumin, but with a stronger and 
quicker extent. These apoptotic features appear to be associated with loss of mitochondrial membrane potential and 
cytochrome c release. In vivo anti-tumor activity of curcumin and D6 was surveyed using sub-cutaneous melanoma and 
orthotopic neuroblastoma xenograft models. D6 treated mice exhibited significantly reduced tumor growth compared 
to both control and curcumin treated ones (Melanoma: D6 vs control: P < 0.001 and D6 vs curcumin P < 0.01; 
Neuroblastoma: D6 vs both control and curcumin: P < 0.001).
Conclusions: Our data indicate D6 as a good candidate to develop new therapies against neural crest-derived tumors.
Background
Malignant melanoma (MM) and neuroblastoma (NB) are
different cancers which share a common neuroectoder-
mal origin, besides being dissimilar for all other patholog-
ical aspects such as tissue involvement, metastasis
development and age of onset.
MM, the most lethal skin cancer, preferentially devel-
ops metastases in lymph-nodes and visceral sites (mostly
lung, liver and bone-marrow): it also presents a high fre-
quency of skin metastases. Its incidence rates have
increased continuously during the last decades in fair
skin populations of western countries [1]. When MM is
diagnosed early it can be successfully removed by surgical
resection, and about 80% of cases are dealt with in this
way [2]. However metastatic MM has a very poor prog-
nosis, with a median survival rate of 6 month and a 5-year
survival rate of less than 5% [3].
Neuroblastoma is the most common extracranial solid
tumor of childhood, and accounts for one of every eight
pediatric cancer deaths [4]. The tumor derives from the
developing sympathetic nervous system and most pri-
mary tumors occur within the abdomen, with at least 50%
arising from the adrenal glands [5]. The main feature of
neuroblastoma is its remarkable biological heterogeneity,
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which becomes apparent in the broad variety of the clini-
cal courses of the disease [6]. Besides, at least 40% of all
children with neuroblastoma are designated as high-risk
patients, meaning that this disease remains a major prob-
lem in pediatric oncology.
Both these tumors are refractory to conventional che-
motherapy and/or radiation treatment actually in use,
hence search for novel therapies is warranted and new
therapeutic approaches are needed. Curcumin  (diferu-
loylmethane) is the main product extracted from the rhi-
zome of Curcuma Longa, a tropical plant native to South
and Southeast Asia. It appears as a yellow powder and it
is routinely used in the cuisine of the Indian subcontinent
as a major component of curry spice. Described in the
ancient test of Ayurveda and traditional Chinese medi-
cine for thousands of years, curcumin has been used for
the treatment of different inflammatory diseases [7]. As a
medicine,  curcumin  exhibits remarkable anti-oxidant,
anti-inflammatory and anti-cancer activities [8]. Chemo-
preventive and growth inhibitory activities of curcumin
against many tumor cell lines, including drug-resistant
ones, have been reported [9]. Taking into account the
complexity and involvement of multiple signaling path-
ways in cancer growth and progression, a drug such as
curcumin, which can interact with multiple target mole-
cules, would be more efficacious than the current mono-
targeted anticancer drugs [10]. Indeed, curcumin targets
several steps in the biochemical pathways leading to can-
cer (see [9] for a review). It suppresses the expression of
cyclin D1, which is deregulated in several types of tumor,
and it also induces apoptosis in tumor cells by activating
caspase-8, which leads to cleavage of Bid, thus resulting
in sequential release of mitochondrial cytochrome c and
activation of caspase-9 and caspase-3, cleavage of poly
ADP ribose polymerase (PARP) and apoptosis of tumor
cells. Moreover curcumin  suppresses the activation of
several transcription factors that are implicated in car-
cinogenesis: it suppresses the activation of nuclear factor
kappa B (NFkB), activator protein 1 (AP-1), and at least
two of the signal transducer and activator of transcription
proteins (STAT3, STAT5). Curcumin  also modulates
expression of genes involved in cell proliferation, cell
invasion, metastasis, angiogenesis, and resistance to che-
motherapy [11] and it shows a potent chemopreventive
activity against a wide variety of tumors. Recently, cur-
cumin has been reported to exert a good antiproliferative
activity on melanoma cells by inducing apoptosis [12]. In
several types of human melanoma cells, curcumin
induces apoptosis through the Fas receptor/caspase-8
pathway independent of p53 and suppresses the anti-
apoptotic gene XIAP [13]. Overall, several pilot clinical
trials using curcumin against various tumors have been
reported; however, its concentration levels in serum and
tissues have been demonstrated to remain very low due
to its poor bioavailability and high instability under phys-
iological conditions [9].
A number of curcumin related compounds have been
synthesized by our group and tested in vitro in order to
select new antitumor agents displaying stronger and
selective growth inhibition activity on melanoma cells
(unpublished data). It has been previously reported that
hydroxylated biphenyl structures could be effective as
cytotoxic agents in MM and NB cells, with apoptotic
inducing capability [14]. On this basis we evaluated the
possibility to design a molecule that, while keeping or
improving the biological properties of curcumin, could
exploit the activity of hydroxylated biphenyl compounds,
which are generally more bioavailable. In this paper, we
describe the synthesis of the new curcumin-related
biphenyl compound D6, an α,β-unsaturated ketone, and
test its anticancer properties. Antiproliferative and
proapoptotic activity of D6 has been assessed by in vitro
experimental procedures on MM and NB cell lines show-
ing D6 more effective than curcumin in inhibiting tumor
cells growth and inducing apoptosis by involving the
intrinsic pathway. In vivo assays on both MM and NB
mouse models have also been carried out, confirming the
D6 anticancer potentiality.
Methods
Chemicals
Curcumin (D1, Figure 1) was purchased from Alfa Aesar
(GmbH & Co KG, Karlsruche, Germany), with a purity of
95%, dissolved in dimethyl sulfoxide (DMSO) at a final
concentration of 100 mM and stored at -20°C until used.
For  in vitro experiments, D1 was diluted in complete
medium to contain <0.1% DMSO, immediately before
use. For in vivo experiments, D1 was diluted in a sterile
0.9% (w/v) NaCl solution containing 1.65 mg/ml bovine
serum albumin (BSA, Sigma, St. Louis, MO, USA) and
3.6% DMSO (v/v), as reported with slight modifications
Figure 1 Chemical structures. Curcumin D1 and related biphenyl D6 
with its precursors (1) and (2).
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[15,16]. D1 dilutions were freshly prepared immediately
before injection and protected from light.
Pan-caspase inhibitor (z-VAD-FMK) was purchased
from Sigma.
Synthesis of D6
The new curcumin-related biphenyl compound, the α,β-
unsaturated ketone D6 was synthesized as follow (Figure
1):
Preparation of 2,2',3,3'-tetramethoxy-5,5'-diformyl-1,1'-
biphenyl (2).
CH3I (1.41 g, 9.93 mM) was added, dropwise at RT
under N2, to a solution of 2,2'-dimethoxy-3,3'-dihydroxy-
5,5'-diformyl-1,1'-biphenyl (1) [17] (1.0 g, 3.31 mM) and
K2CO3 (1.37 g, 9.93 mM) in 20 ml of dry acetone. The
solution was stirred at reflux for 12 hours and washed
with water (100 ml). The organic phase was extracted
with ether (2 × 100 ml) and dried over Na2SO4 to obtain a
yellow solid. The crude material was purified by flash
chromatography using a 6:4 mixture of petroleum:ace-
tone as eluent to give (2) as a white solid. (0.87 g, 80%):
mp 130-131°C; 1H NMR δ 3.76 (s, 6H), 3.97 (s, 6H), 7.38
(d, J = 2.0 Hz, Ar, 2H), 7.49 (d, J = 2.0 Hz, Ar, 2H), 9.90 (s,
2H);  13C NMR δ 56.07, 60.99, 110.17, 127.44, 131.57,
131.87, 152.11, 153.15, 190.69; Anal. Calcd for C18H18O6:
C, 65.45; H, 5.49; Found: C, 65.55; H, 5.38.
Preparation of (3E,3'E)-4,4'-(5,5',6,6'-tetramethoxy-
[1,1'-biphenyl]-3,3'-diyl)bis(but-3-en-2-one) (D6).
A 1 N solution of NaOH (1.6 ml) was added, dropwise,
to a solution of 2,2',3,3'-tetramethoxy-5,5'-diformyl-1,1'-
biphenyl (2) (1.65 g, 0.5 mM) in dry acetone (10 ml). The
solution was stirred at RT for 12 hours. The solvent was
evaporated. 10% HCl was added (100 ml), the organic
phase was extracted with dichloromethane (2 × 100 ml)
and dried over Na2SO4 to obtain a yellow solid. The crude
material was purified by flash chromatography using a 6:4
mixture of petroleum: acetone as eluent to give (D6) as a
white solid. (1.07 g, 52%): mp 166-167°C; 1H NMR δ 2.35
(s, 6H), 3.69 (s, 6H), 3.95 (s, 6H), 6.63 (d, J = 16.4 Hz, 2H),
7.05 (d, J = 2.0 Hz, Ar, 2H), 7.11 (d, J = 2.0 Hz, Ar, 2H),
7.45 (d, J = 16.4 Hz, 2H); 13C NMR δ 27.46, 55.91, 60.85,
110.80, 124.10, 126.47, 129.82, 132.32, 143.04, 149.05,
153.02, 198.22; Anal. Calcd for C24H26O6: C, 70.23; H,
6.38; Found: C, 69.89; H, 6.48.
Cell lines and culture conditions
Malignant melanoma (MM) cell lines [LB24Dagi (LB24),
CN-MelA (CN), GR-Mel (GR), WM266-4 (WM), 13443,
and M14] were a gift from Dr. D. Castiglia at Istituto Der-
mopatico dell'Immacolata, Department of Molecular and
Cellular Biology, in Rome, as reported [14]. The following
human neuroblastoma (NB) cell lines were used: GI-LI-
N, HTLA-230, SH-SY5Y, LAN5, SK-NBE2c, and IMR-32
[18,19]. Normal human fibroblasts BJ (CRL-2522) were
purchased from the American Type Culture Collection
(ATCC) and served as controls. All cells were grown
either in Dulbecco's minimal essential medium (DMEM,
Sigma) or in RPMI medium (Invitrogen, Carlsbad, CA,
USA), as described [14,18,19].
Cell proliferation assay
All MM (3-5 × 103 per well) and NB (8-12 × 103 per well)
cell lines were plated in 96-well plates in complete
medium and treated in quadruplicate with different con-
centrations of either D1/D6 (0-25 μM) or 0.1% DMSO
(control) for 72 hours. The percentage of MM cell prolif-
eration was estimated on day 5 by the colorimetric assay
of Kueng et al. [20] modified as previously reported [21].
Neuroblastoma cells were incubated overnight with 0.5
μCi (0.0185 MBq) 3H-thymidine (Amersham Bioscience,
Little Chalfont, UK) and processed for liquid scintillation
counting (Packard Instruments Company, Downers
Grove, IL, USA), as described [19].
To assess the effect of duration of drug exposure on cell
proliferation, we also performed drug washout experi-
ments, according to the method described by Keshelava
et al. [22]. Briefly, the D1/D6-containing medium was
removed from the cultures after 6 or 12 hours by washing
the cells twice with complete medium. The cells were
subsequently covered with fresh drug-free complete
medium and incubated for a total incubation time of 72
hours. Cell proliferation was evaluated by either measur-
ing DNA synthesis as a function of 3H-thymidine uptake
or by the colorimetric assay, as above [19,21].
Clonogenic cell survival assay
MM (LB24) and NB (GI-LI-N) cells were suspended at
concentrations of 3 × 105 cells/ml, treated with either D1
or D6 (0, 2.5, 5, 10, or 20 μM) in culture medium for 4
hours and then plated (in triplicate) at 50 (LB24) and 300
(GI-LI-N) cells per well into 12-well plates with fresh
drug-free medium. Cells were incubated for an additional
14 days, then the colonies in each well were stained,
counted and photographed [18].
Apoptosis assays
Terminal deoxynucleotidyl transferase-mediated dUTP nick 
end labeling (TUNEL) assay
LB24 melanoma cells and BJ fibroblasts were plated in 8
well-chamber slides (5 × 104 and 5 × 105/well, respec-
tively), cultured for 24 hours, and then treated with either
D1 or D6 (10 μM). After further 24 hours, DNA cleavage
was assessed by enzymatic end-labeling of DNA strand
breaks using a commercial kit (In Situ Cell Death Detec-
tion Kit, Roche, Penzberg, Germany), according to the
manufacturer's instructions and as previously reported
[14].Pisano et al. Molecular Cancer 2010, 9:137
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Phosphatidylserine detection
For detection of phosphatidylserine exposure, cultured
LB24 cells (1 × 106/25 cm2 plastic culture flask) and GI-
LI-N cells (2 × 106/25 cm2 plastic culture flask) were
treated with either D1 (10 μM) or D6 (5 μM and 10 μM),
collected, washed and processed using a human Annexin-
V FITC kit (Bender MedSystems, Vienna, Austria),
according to manufacturer's instructions and examined
by two-color flow cytometry using a FACScan device
[18,14].
Caspase 3/7 activation
Detection of caspase 3/7 cleavage activity was done using
the Apo-ONER Homogeneous Caspase 3/7 Assay (Pro-
mega, Madison, WI, USA). GI-LI-N, SH-SY5Y, IMR-32,
LB24 and M14 cell lines were seeded in 96-well plates
(10-20 × 103/well). Cells were then treated with D1 or D6
at a concentration of 10 μM and 5 μM, respectively, for 24
hours. In some experiments, cells were treated for 1 hour
with 100 μM z-VAD-FMK caspase inhibitor before D1
and D6 administration. At the end of treatment, 100 μl of
the Apo-ONE Caspase 3-7 Reagent was added to each
well, according to manufacturer's instructions. Cells were
then incubated at room temperature in a plate shaker
(400 rpm) for 3 hours. Fluorescence was detected (485
nm excitation wavelength and 535 emission wavelength)
using a fluorescence plate reader (SPECTRAFluor Plus,
TECAN Austria, GmbH, Grodig/Salzburg, Austria). The
amount of fluorescent product generated is proportional
to the amount of caspase 3/7 cleavage activity present in
the sample.
Mitochondrial membrane potential assay
The mitochondrial permeability transition event was
detected by MitoPT kit (Immunochemistry Technolo-
gies, LLC, Bloomington, MN, USA) according to the
manufacturer's instructions. Briefly, IMR-32 and LB24
cell lines were plated in 6-well flat-bottomed plates (0.7 ×
106/well and 0.4 × 106/well, respectively). The cells were
then treated with both D1 and D6 (2.5-10 μM and 5-10
μM, respectively) for 18 hours, harvested, and processed
as previously described [18,19]. The analysis was per-
formed using a FACS Calibur (Beckton Dickinson, Frank-
lin Lakes, NJ, USA). As the mitochondrial membrane
potential collapsed (apoptosis), the amount of red fluo-
rescence decreased.
Western blot analysis
Total cell lysates were prepared and analyzed by western
blot analysis as described earlier [18,19]. Briefly, both
MM and NB cell lines were untreated or treated with
either D1 (10 μM) or D6 (5 μM) for 18, 24 or 48 hours and
then lysed with Cell Extraction Buffer (BioSource Inter-
national, Camarillo, CA, USA) plus protease inhibitor
cocktail (Sigma). To obtain subcellular fractions, the cells
were processed with Qproteome Cell Compartment kit,
according to the manufacturer's instructions (Qiagen,
Crawley, UK), and resuspended with the above-men-
tioned lysis buffer. Protein lysates (50 μg per lane) were
resolved on sodium dodecyl sulphate (SDS) 10 to 14%
polyacrylamide gels and transferred to nitro-cellulose
membranes; the membranes were then incubated with
mouse monoclonal antibodies against procaspases 3, 9
(Cell Signaling Technology, Danvers, MA, USA) and
NFkB (BD), or rabbit monoclonal antibody against PARP
(Abcam, Cambridge, UK) or polyclonal antibody against
cytochrome c (Cell Signaling Technology). Peroxidase-
conjugated goat anti-mouse and anti-rabbit antibodies
were used as secondary antibodies (Upstate, Lake Placid,
NY, USA and Santa Cruz Biotechnology, Santa Cruz, CA,
USA, respectively). Immune complexes were visualized
with the use of an ECL Advance Western Blotting Detec-
tion kit (Amersham Bioscience), according to the manu-
facturer's instructions, and normalized to internal
controls [a rabbit antibody against GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase) (Sigma) and a mouse
antibody against Lamin A/C (BD)].
Animal models
All animals were purchased from Harlan Laboratories
(Harlan Italy, S.Pietro al Natisone, Italy) and housed
under specific pathogen-free conditions. All experiments
involving animals have been reviewed and approved by
the licensing and ethical committee of the National Can-
cer Research Institute, Genoa, Italy and by Italian Minis-
try of Health. All the in vivo experiments were performed
using 5-week-old female athymic (nude-nu), 5 to 8 mice
per group and repeated at least twice with similar results.
For the melanoma animal model, 1.5 × 106 LB24 cells
were injected subcutaneously (s.c.) in the mid-dorsal of
the mice, as previously reported [23]. Tumors were
allowed to grow for 5 days, reaching a size of about 10
mm3, before intravenous (i.v.) treatment into tail vein.
For the neuroblastoma animal model, 1.5 × 106 GI-LI-N
cells were orthotopically injected in the capsule of the left
adrenal gland of mice, as described previously [24,19]. In
another set of experiments, mice were orthotopically
injected with 1.5 × 106  luciferase-transfected GI-LI-N
cells to monitor in vivo orthotopic tumor growth over
time by bioluminescence imaging (BLI) [25].
In vivo therapeutic studies
In order to administer D1 and D6 by intravenous route
(for a rapid and efficacious drug distribution), we have
pre-dissolved curcuminoids in DMSO at 10 mM and then
diluted in a saline solution containing BSA, as previously
suggested by others (15, 16) and by us (19) for water-
insoluble compounds. In the melanoma animal model,
after tumor growing as above, mice were randomly
assigned to three groups (8 mice/group) and treated withPisano et al. Molecular Cancer 2010, 9:137
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D1, D6 or with saline solution (control mice). Either D1
or D6 were i.v. injected at 17.5 mg/Kg twice a week for a
total of 7 times. Moreover, at both 2 hours post the first
injection and one day after the last one, four mice of each
group of treatment were subjected to blood sample to test
acute and chronic liver and renal toxicity using an auto-
matic analyzer Kuadro Liquid Vet (BPC BioSed, Rome,
Italy). Tumors were measured twice weekly with calipers
and volume were calculated by the formula 4/3 π axbxc
where a, b and c represented the values of all symmetric
axes that constitute the ellipsoid tumor mass. At the end
of the treatment, mice were killed by cervical dislocation
after being anesthetized with xylazine (Xilor 2%; Bio98
Srl, Milan, Italy), and their tumors were measured with
caliper and then weighted.
For neuroblastoma animal model, tumors were allowed
to grow for 14 days, and then mice, randomly assigned to
three groups (8 or 5 mice/group), were treated with the
same schedule used for the above melanoma animal
model.
In all experiments, body weight and general physical
status of the animals were recorded daily until they were
judged to be in discomfort by animal caretakers. Specifi-
cally, once showing signs of poor health (i.e., abdominal
dilatation, dehydration, paraplegia, severe weight loss)
mice were euthanized, following anesthesia with xylazine
and the day of euthanasia was recorded as the day of
death.
Statistical analysis
All in vitro data derive from at least three independent
experiments and results are expressed as mean values
with 95% confidence intervals. The statistical significance
of differential findings between experimental and control
groups was determined by ANOVA with the Tukey's mul-
tiple comparison test in Graph-Pad Prism 3.0 software
(Graph-Pad Software, Inc, San Diego, CA, USA). These
findings were considered significant if two-tailed P values
were <0.05. Survival curves have been constructed with
the Kaplan Meier method. All the in vivo experiments
were performed at least twice with similar results. A P
value less than 0.05 has been considered as statistically
significant by the use of the Peto's log-rank test in Graph-
Pad Prism 3.0 software.
Results
Effects of D1 and D6 on proliferation, clonal growth and 
viability of melanoma and neuroblastoma cell lines
Cell proliferation assays were performed to assess the
cytotoxic activity of the novel biphenyl, curcumin-related
compound D6 (see Figure 1) in comparison with that of
curcumin  D1. Figure 2 shows the dose-dependent cell
growth inhibition of 6 NB cell lines treated with either D1
(panel A) or D6 (panel B), clearly evidencing the stronger
efficacy of D6 at very low doses (1-2.5 μM) after three
days of treatment. MM cells growth inhibition gave simi-
lar results and a summary of all the IC50 values obtained
at 72 hours for MM and NB cell lines for both com-
pounds is reported in figure 2, panel C. Considering the
IC50 mean values ± s.d. obtained for all NB and MM cell
lines tested we can note that D6 is about 5-10 fold more
efficient than D1 in both cases.
To assess the impact of D6 exposure time on cell prolif-
eration, washout experiments were performed. These
experiments simulated the in vivo activity of D6, testing
the minimum time of response of the tumor cells to the
drug. D6 action was very powerful and rapid in arresting
NB and MM cells growth: a single 6 hours treatment was
sufficient to inhibit tumor cells proliferation up to 75-
90%, having a small effect (10-20%) on BJ normal fibro-
blasts (Figure 2, panels D, E). Moreover cell proliferation
capability was not restored when cells were grown in the
absence of the drug up to 72 hours, showing that the anti-
proliferative effect of D6 was irreversible. Washout exper-
iments performed using D1 instead, did not show any
appreciable activity on cell proliferation for both type of
tumor cells (Additional file 1 Figure S1).
To measure long-term effects of D1 and D6 on perma-
nent cell growth arrest and cell death we performed clo-
nogenic survival assays. Clonal growth of both LB24
melanoma cells and GI-LI-N neuroblastoma cells was
inhibited by D6 in a dose dependent manner as shown in
figure 3. Conversely, D1 was not able to abolish colony
formation under the same conditions, but partly inhibited
clonogenic growth only at the highest concentration used
(20 μM).
D1 and D6 induce apoptosis in both melanoma and 
neuroblastoma cells
To determine whether the observed D1- and D6-induced
reduction in viability of both melanoma and neuroblas-
toma cell lines occurred via activation of apoptosis, we
used TUNEL staining to highlight DNA fragmentation
and Annexin-V assay, in which Annexin-V binds to exter-
nalized phosphatidylserine on the surface of apoptotic
cells. TUNEL assay in figure 4, panel A shows a higher
proportion of apoptotic melanoma cells in the D6 treated
sample compared to the D1 treated one, while human BJ
fibroblast cells appear not to be affected by these treat-
ments. Furthermore, when LB24 melanoma cells were
exposed for 24 and 48 hours to 5 and 10 μM of both D1
and D6, a significant, time- and dose-dependent, increase
in the percentage of Annexin-V-positive cells was
observed, particularly following D6 treatment (Figure 4,
panel B). Similar results were obtained with GI-LI-N neu-
roblastoma cells (Figure 4, panel C). (*, P < 0.05; **, P <
0.01; ***, P < 0.001 vs untreated cells).Pisano et al. Molecular Cancer 2010, 9:137
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Activation of aspartate specific cysteine proteases or
caspases may be involved in induction of apoptosis [26].
Caspase 3/7 assays showed that both D1 and D6 (at 10
μM and 5 μM, respectively) significantly induced the
cleavage of caspases 3 and 7 in GI-LI-N neuroblastoma
cells and LB24 melanoma cells (Figure 5, panels A and B,
respectively). In both cases D1 and D6 vs control showed
a very significative value ***, P < 0.001 and the effect of
D6 was stronger when compared to D1 for both cell lines.
A pre-incubation with the pan-caspase inhibitor z-VAD-
FMK completely abolished the D1 and D6-induced cas-
pases 3 and 7 cleavage activity, meaning that caspases are
involved in this cell death. Since activation of caspases 3
and 7 has been reported to also belong to the intrinsic
apoptotic signaling pathway [27,28], we decided to inves-
tigate mitochondria-related events, mitochondrial mem-
brane damage and release of the cytochrome c into the
cytosol, which is putatively involved in the curcuminoids-
triggered cell death. The percentage of both IMR-32 and
LB24 cells with polarized mitochondria decreased after
18 hours treatment with the above mentioned doses of
D1 and D6: this reduction was statistically significant and
highlighted, also in this context, the major sensitivity of
neuroblastoma cells to D6 (Figure 5, panel C: IMR-32: D1
vs control: *, P < 0.05 and D6 vs control: ***, P < 0.001;
LB24: both D1 and D6 vs control: *, P < 0.05). The result-
ing release of cytochrome c from mitochondria appeared
more consistent after D6 treatment in both IMR-32 and
LB24 cell lines (Figure 5, panel D). Consistently, this event
led to caspase 9 activation in both NB and MM cells, indi-
cating that, together with the disruption of mitochondrial
membrane potential, the intrinsic apoptotic pathway was
involved in this gene activation cascade. Moreover, the
level of pro-caspase 3 was also decreased in response to
Figure 2 Effects of D1 and D6 on the growth of human neuroblastoma and melanoma cell lines. (A), (B): Six NB cell lines were cultured in the 
presence of various concentrations (0-25 μM) of D1 (A) and D6 (B) or 0.1% DMSO (control cells) for 72 hours. Cell proliferation was measured by 3H-
thymidine incorporation. Results, derived from three different experiments, are expressed as mean percentage of 3H-thymidine incorporation from 
quadruplicate wells as compared to that of control cells. Error bars represent 95% confidence intervals. (C) IC50 values obtained on the six NB cell lines 
and the six MM cell lines reported in the M&M section. (D) and (E): drug washout assays to assess the impact of D6 time exposure on cell proliferation 
in NB cells (D), MM cells and BJ fibroblasts (E). Cells were incubated with D6 for the indicated times and concentration and then washed and cultured 
in drug-free medium up to 72 hours. Cell proliferation was assessed by 3H-thymidine incorporation. Results are expressed as described above.
(C)
1,4 ± 0,3 7,7 ± 1,1 1,8 ± 0,9 10,2 ±1 , 9
D6 D1 D6 D1
NB MM
IC50 (M) at 72 hours
(E)
WO 6 hours WO 12 hours
0
25
50
75
100
LB24
CN
GR
WM
13443
BJ
D6 (5 μ μ μ μM)
3
H
-
t
h
y
m
i
d
i
n
e
i
n
c
o
r
p
o
r
a
t
i
o
n
(
%
 
o
f
 
c
o
n
t
r
o
l
)
(D)
3
H
-
t
h
y
m
i
d
i
n
e
i
n
c
o
r
p
o
r
a
t
i
o
n
(
%
 
o
f
 
c
o
n
t
r
o
l
)
0
25
50
75
100
SH-SY5Y
SK-NBE2c
LAN-5
HTLA-230
GI-LI-N
D6 (5 μ μ μ μM)
WO 12 hours WO 6 hours
(A)
D1 (μ μ μ μM)
0.1
0.5
1.0
2.5
5.0
10.0
25.0 0
25
50
75
100 SH-SY5Y
SK-NBE2c
LAN-5
HTLA-230
GI-LI-N
IMR-32
3
H
-
t
h
y
m
i
d
i
n
e
i
n
c
o
r
p
o
r
a
t
i
o
n
(
%
 
o
f
 
c
o
n
t
r
o
l
)
(B)
D6(μ μ μ μM)
0.1
0.5
1.0
2.5
5.0
10.0
25.0
0
25
50
75
100 SH-SY5Y
SK-NBE2c
LAN-5
HTLA-230
GI-LI-N
IMR-32
3
H
-
t
h
y
m
i
d
i
n
e
i
n
c
o
r
p
o
r
a
t
i
o
n
(
%
 
o
f
 
c
o
n
t
r
o
l
)Pisano et al. Molecular Cancer 2010, 9:137
http://www.molecular-cancer.com/content/9/1/137
Page 7 of 12
D6 treatment and this event culminated in the cleavage of
poly(ADP)ribose polymerase (PARP), confirming the
occurring of programmed cell death (Figure 5, panel E).
In vivo anti-tumor activity of D1 and D6 against human 
neuroectoderma-derived xenografts
We used two previously described animal models, a sub-
cute tumor model for melanoma [23] and an orthotopic
xenograft model for neuroblastoma [19] to evaluate
whether D1 and D6 would inhibit neuroectoderma-
derived cell growth in vivo.
In cancer related research, curcuminoids have been
used in cell culture systems, animal models and clinical
trials [9,29,30]. Unfortunately, the study of curcuminoids
is severely limited by their extremely low bioavailability
following oral administration. Moreover, only predissolv-
ing curcuminoids in DMSO render them in a physical
form, that is proper for solubilization in aqueous media
containing serum or preferentially BSA [16]. Then, in a
set of preliminary experiments, we have injected D1 and
D6 in the tail vein and we have been able to obtain good
animal responses to a restrict range of administered
doses (15-25 mg/Kg), in terms of good health (i.e., no
abdominal dilatation, dehydration, paraplegia, severe
weight loss), together with slightly variations in both liver
and renal enzymatic values, only at the higher doses
throughout the experiments. Therefore, after both subcu-
taneous injection of LB24 melanoma cells and orthotopic
implantation of GI-LI-N neuroblastoma cells, we treated
mice with 17,5 mg/Kg of D1 and D6 by i.v. injection twice
a week, for 7 times.
In melanoma-bearing mice (Figure 6, panel A), both D1
and D6 induced a significant inhibition of tumor growth
when compared to that of untreated mice. Noteworthy,
the D6 inhibitory effect was already evident at early days
of treatment, and it was more statistically efficacious than
D1 (D6 vs D1, P < 0.01). The pronounced delay in tumor
growth, especially by D6, was translated into tumor
weight values, which have been obtained at the end of the
treatment (Figure 6, panel B: both D1 and D6 vs control,
***, P < 0.001; D6 vs D1, *, P < 0.05).
Figure 3 Effects of D1 and D6 on the clonogenic growth of mela-
noma (LB24) and neuroblastoma (GI-LI-N) cell lines. Cells have 
been suspended in drug-containing medium at different concentra-
tions (0-20 μM) of D1 and D6 for 4 hours and then washed, seeded with 
drug-free medium in a 12 well-plate and let grow up to 14 days. Cell 
colonies were stained with crystal violet, counted and photographed 
as described in M& M.
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Figure 4 Effects of D1 and D6 on apoptosis in melanoma and neu-
roblastoma cells. (A) Melanoma cells (LB24) and normal fibroblasts 
(BJ) were incubated with solvent (control), or with 10 μM D1 and D6 for 
24 hours, then stained by TUNEL assay. Apoptotic cells are visualized 
by red staining. Cell nuclei (blue) were stained with DAPI (bar, 100 μm). 
(B) Melanoma cells (LB24) and (C) Neuroblastoma cells (GI-LI-N) were 
incubated with 10 μM D1 and with 5 and 10 μM D6 for 24 and 48 hours. 
Apoptosis induction was determined as the percentage of Annexin-V 
positive cells. Columns: means; bars: SD. *, P < 0.05; **, P < 0.01; ***, P < 
0.001 vs control levels.
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Figure 5 D6 and D1 triggered-apoptosis is caspase-dependent and involves the apoptotic intrinsic pathway. (A) and (B): Caspase 3/7 activa-
tion was assessed on GI-LI-N cells (A) and LB24 cells (B), untreated (control), or treated with D1 (10 μM) and D6 (5 μM) for 24 hours. Cells received an 
1 hour pre-treatment with a pan-caspases inhibitor (z-VAD-FMK). RFU: Relative Fluorescence Unit. ***, P < 0.001 vs control. (C) To assess the effects of 
drugs on mitochondrial membrane permeability, neuroblastoma IMR-32 and melanoma LB24 cells were untreated (control) or treated with D1 and 
D6, as above, for 18 hours, harvested, and analyzed for changes in mitochondrial membrane potential. Results are expressed as the mean percentage 
of cells with polarized mitochondria from four independent experiments; error bars, 95% CIs. *, P < 0.05; ***, P < 0.001 vs control. (D) IMR-32 and LB24 
cells were treated for 24 hours as above and fractionated cellular lysates were analyzed by western blot with a specific primary antibody for cyto-
chrome c. GAPDH was used as loading control. (E) SH-SY5Y, HTLA-230, GI-LI-N neuroblastoma cell lines and LB24, M14, WM melanoma cell lines were 
treated as in panel D for 48 hours and total cellular lysates were analyzed by western blot with specific primary antibodies for procaspase 9, procaspase 
3 and poly(ADP)ribose polymerase (PARP). As for (D), blots are representative of three independent experiments and data were normalized against 
GAPDH.
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Even in the neuroblastoma animal model, D6 induced a
statistically significant more pronounced tumor growth
reduction than D1 evaluated by means of BLI (Figure 6,
panel C: D6 vs both D1 and control, P < 0.001). More
importantly, the survival rate was significantly increased
only by the D6 treatment (Figure 6, panel D: D6 vs con-
trol, P = 0.0007; D6 vs D1, P = 0.0169).
In the two experimental animal models, the mean body
weight of both D1 and D6-treated mice was not signifi-
cantly lower than that of saline-injected (control) mice,
indicating that the molecules had minimal side effects
(Insets, Figure 6, panels A and C). Besides, this good sys-
temic tolerability was also confirmed by the trend of both
liver and renal enzymatic values throughout the experi-
ments (Additional file 2 Table S1).
Discussion
Despite the current advances in anticancer therapies, the
clinical prognosis of both malignant melanoma and
aggressive neuroblastoma remain fatal. For this reason
search of effective novel drugs, with low systemic toxicity,
is a main field in oncology research.
Curcumin, which is a natural derived compound, con-
sidered pharmacologically safe even at high doses [31],
has been shown to prevent tumor formation and progres-
s i o n  i n  m a n y  c a n c e r  t y p e s  a s  w e l l  a s  t o  e x e r t  g r o w t h
inhibitory effects on several neoplastic cells [10]. In this
Figure 6 In vivo anti-tumor activity of D1 and D6. (A), (B): in the melanoma animal model, nude mice (n = 8 mice/group) received i.v. 17.5 mg/kg 
of D1 and D6 or saline solution (control mice) on day 5 after s.c. injection of 1.5 × 106 LB24 cells, twice a week, for 7 times. (A) Tumor volumes were 
measured at different times points after cell inoculation. P values were calculated using Peto's log-rank test (**, P < 0.01; ***, P < 0.001). Inset: absolute 
mean body weight, in grams, after the beginning of the treatment. (B) Two days after the end of the treatment, mice were sacrificed and tumors were 
excised and weighted. Bars depict the mean values and error bars represent 95% confidence intervals. P values were calculated using ANOVA with 
Tukey's multiple comparison test (*, P < 0.05; ***, P < 0.001). (C): Nude mice were orthotopically injected with 1.5 × 106 luciferase-transfected GI-LI-N 
neuroblastoma cells and tumors were allowed to grow for 14 days, then mice, randomly assigned to three groups (5 mice/group), were treated with 
the same schedule used for the above melanoma animal model. Orthotopic tumor growth was monitored over time by bioluminescence imaging 
(BLI). P values were calculated using Peto's log-rank test (***, P < 0.001). Inset: absolute mean body weight, in grams, after the beginning of the treat-
ment. (D) Therapeutic effects on survival were evaluated on nude mice (n = 8 mice/group) orthotopically injected with 1.5 × 106 GI-LI-N cells in the 
left adrenal gland and treated as above. Survival of mice was monitored daily. P = 0.0007 for D6 over control and P = 0.0169 for D6 over D1.
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study, we demonstrated that a newly-synthesized cur-
cumin-related biphenyl compound, the α,β-unsaturated
ketone D6, acts as a very promising anticancer molecule,
being more effective than curcumin  in inhibiting neu-
roectodermal derived cancer cells growth by inducing
apoptosis. In particular, D6 caused proliferation arrest in
cultured NB and MM cells at low concentrations (1-5
μM), whereas curcumin reached the same effects at con-
centrations 5-10 fold higher. Moreover D6 treatments
had no effect on normal fibroblasts at the same concen-
trations suggesting that this compound shows preferen-
tial cytotoxic activity on cancer cells. In vitro response to
a given drug could be influenced by cell culture condi-
tions: usually, cells grown in monolayer are more sensi-
tive to cytotoxic agents than cells grown in colonies
because of the larger surface they expose to the drug,
compared to the limited drug penetration in the colonies
[32]. Moreover in vivo growth rate of solid tumors is typi-
cally lower than that of in vitro monolayer cultures. Our
results showed that D6 is similarly efficient in suppress-
ing  in vitro proliferation of NB and MM cells in both
monolayer and colony cell culture conditions. This find-
ing suggests that D6 could probably exploit its in vivo
anticancer activity without being influenced by the low
fraction of proliferating cells in solid tumors, which is a
limit of many of the conventional cell cycle-dependent
chemotherapeutic agents [33].
Several studies indicated curcumin  as a proapoptotic
agent against different types of cancer cells (reviewed in
[9]); therefore, we investigated whether D6-driven prolif-
eration arrest was due to induction of apoptosis. In our
experiments, both NB and MM cells presented apoptosis
following D6 treatments. Moreover, a more consistent
portion of apoptotic MM cells was observed in cells
treated with D6 compared to those treated with cur-
cumin. Interestingly, no evidence of apoptosis was
observed in normal human BJ fibroblasts grown in the
same conditions, again suggesting the preferential anti-
proliferative activity of D6 on cancer cells.
Induction of apoptosis may also involve activation of
aspartate specific cysteine proteases or caspases. Our
results show that activation of both caspase 3 and caspase
7 occurred after treatment of NB and MM cells with D6,
again being more efficient than the treatment with D1.
One of the hallmark of caspase activation is polyadenos-
ine-5'-diphosphate-ribose-polymerase (PARP) cleavage,
where the native 116 kD polypeptide is cleaved to a
smaller 85 kD fragment. Usually, PARP inactivation is
dependent on caspase 3, which has a central role in the
apoptosis process collecting signals coming from both
intrinsic and extrinsic pathways. Induction of apoptosis
by curcumin has been reported to occur through both
mitochondrial intrinsic pathway [34] and death receptor
mediated extrinsic pathway [13]. Cleavage of procaspase
9 in the D6 treated cells suggested the involvement of
mitochondrial pathway in the mechanism of action of
this compound; indeed, this hypothesis was validated by
the observation of mitochondrial membrane depolariza-
tion. Noteworthy, all the apoptosis hallmarks were found
significantly higher in D6-treated than curcumin/D1-
treated cells, strongly suggesting that D6 may act as a
more effective proapoptotic agent.
Considering our in vivo data, both NB and MM xeno-
g r a f t s  s h o w e d  a  g o o d  r e s p o n s e  t o  t h e  D 6  t r e a t m e n t s :
tumor mass growth was significantly reduced compared
to control mice, especially after the D6 administration.
Importantly, the survival time increased in a statistically
significant way among D6 treated mice, while no evident
side effects were observed. On this regard, mean body
weight of treated mice was not affected by either D1 or
D6 administration and both liver and renal functionality
showed to be normal (see Additional file 2 Table S1).
These findings confirmed that this class of compounds,
such as curcumin, has good tolerability and an interesting
anticancer proapoptotic activity.
Curcumin has been reported to act as anticancer agent
by suppressing NFkB signaling (reviewed in [35] and [9]).
Constitutively active form of NFkB has been reported in
several human cancers [36] and activated NFkB sup-
presses apoptosis in a wide variety of cancer cells [37].
When we investigated the possible involvement of NFkB
signaling suppression in D6 antiproliferative activity we
found out that our cell lines did not show constitutive
activation of this transcription factor so that probably this
pathway is not involved in the transformation processes
of these cells (see Additional file 3 Figure S2). The cur-
cumin and D6 antiproliferative and proapoptotic action
on our MM and NB cells must be therefore due to differ-
ent mechanisms. Nevertheless, when NFkB activation
and nuclear translocation was induced in NB cells by
TNFα or doxorubicin pretreatments, D1 and, even better,
D6 administration to the cells consistently inhibited
NFkB activation, indicating the capability of these com-
pounds to interfere with such molecular activation of
transcription pathway. The last evidence points out the
potentiality of D6 to be used in combination with chemo-
therapeutic agents which stimulate the activation of gene
transcription through NFkB pathway, such as doxorubi-
cin [38].
Conclusions
In summary, we have demonstrated that hydroxylated
biphenyls structurally related to curcumin are a class of
molecules worth to be studied for its promising antipro-
liferative and proapoptotic features. Moreover, although a
large selection of curcumin  analogues have been pub-
lished and tested as antitumoral agents [39], no examples
of hydroxylated biphenyl curcumin-related have beenPisano et al. Molecular Cancer 2010, 9:137
http://www.molecular-cancer.com/content/9/1/137
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published before. Specifically, D6 activity seems to be
effective, rapid, and selective against both NB and MM
cells, by causing apoptosis in vitro and reduction of
tumor mass growth in mice models in vivo. Such an anti-
proliferative activity seems to be achieved using lower
concentrations than curcumin. As a consequence, D6
could be considered a good candidate to develop new
therapeutic strategies against tumors with neuroectoder-
mal origin.
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